Reinhart Partners’s GSK GSK Stock Holding History

Reinhart Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-8,456	Closed	-$429K	–	105
2016 Q1	$429K	Sell	8,456 -1,624	-16%	-$80.9K	0.04%	82
2015 Q4	$508K	Sell	10,080 -30,180	-75%	-$1.54M	0.05%	84
2015 Q3	$1.94M	Sell	40,260 -956	-2%	-$49.8K	0.19%	68
2015 Q2	$2.15M	Sell	41,216 -190,196	-82%	-$10.7M	0.2%	70
2015 Q1	$13.3M	Buy	231,412 +41,852	+22%	+$2.4M	0.97%	44
2014 Q4	$10.1M	Buy	189,560 +53,984	+40%	+$3.02M	0.75%	47
2014 Q3	$7.79M	Buy	135,576 +6,708	+5%	+$411K	0.57%	55
2014 Q2	$8.62M	Sell	128,868 -29,828	-19%	-$2.02M	0.62%	55
2014 Q1	$10.6M	Sell	158,696 -5,132	-3%	-$347K	0.8%	49
2013 Q4	$10.9M	Sell	163,828 -1,500	-0.9%	-$97.3K	0.87%	46
2013 Q3	$10.4M	Buy	165,328 +32,756	+25%	+$2.11M	0.88%	51
2013 Q2	$8.28M	Buy	+132,572	New	+$8.41M	0.76%	52

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Reinhart Partners's GSK Position: Q2 2016 in Review

Reinhart Partners sold out of GSK (GSK) in Q2 2016, closing a stake of 8,456 shares — an estimated $429K sold.

Reinhart Partners first reported a position in GSK in Q2 2013 and held it in 12 quarters. The position peaked at $13.3M in Q1 2015. 741 funds tracked by Wall St. Rank hold GSK as of Q2 2016.

Reinhart Partners reported no remaining GSK position as of Q2 2016 after selling out during the quarter.
Reinhart Partners sold 8,456 GSK shares in Q2 2016, an estimated $429K.
Reinhart Partners first reported a position in GSK in Q2 2013 and held it in 12 quarters.
Reinhart Partners's GSK position peaked at $13.3M in Q1 2015.
741 funds tracked by Wall St. Rank held GSK as of Q2 2016.

Based on Reinhart Partners's 13F filing for Q2 2016, filed 20 Jul 2016.